Beijing Tongrentang (600085) Stock Price, Fundamentals & Analysis

What 600085 does

Beijing Tongrentang (600085) is a stock listed on the Shanghai Stock Exchange in the Healthcare sector, specifically in the Drug Manufacturers – Specialty & Generic industry. The company produces and sells traditional Chinese medicine preparations in China and internationally, offering products in forms such as pills, powders, medicated wines, capsules, oral liquids, and drop pills. Its applications cover areas including cardiovascular, cerebrovascular, gynecology, respiratory, digestive, pediatrics, orthopedics, and mental health, among others. Beijing Tongrentang operates as a subsidiary of China Beijing Tong Ren Tang Group Co. Ltd and was founded in 1997, with headquarters in Beijing, China. It is part of the CSI 300 index and has peers such as Shanghai Pharmaceuticals Holding (601607), Jiangsu Hengrui Medicine (600276), and Fosun Pharmaceutical (600196).

Key numbers explained

• The current price of 23.34 CNY is the most recent trading price; the -1.14% change today shows the session’s move relative to the prior close.
• The trailing P/E ratio of 32.9 compares the stock price to the last 12 months of earnings per share (0.71 CNY); a higher number can indicate investors are paying more for each unit of recent earnings.
• The forward P/E ratio of 21.4 uses expected future earnings, offering a look at how the market prices in growth or decline.
• The dividend yield of 2.14% tells you the annual dividend payment as a percentage of the current price; the exDividendDate is 1 iul. 2026, and 71% of earnings are paid out as dividends.
• The beta of 0.04 suggests the stock’s price movements have historically been much smaller than the overall market’s movements.
• The 52-week range of 21.87 – 35.87 CNY and the -31.8% price change over the last year show the recent price trend.
• The debt-to-equity ratio of 16.5% indicates the company uses relatively little debt compared to shareholder equity.

What to watch

Investors tracking Beijing Tongrentang (600085) often monitor sector trends in traditional Chinese medicine and broader Healthcare dynamics. Regulatory changes in China, pricing policies for pharmaceuticals, and shifts in consumer demand for traditional remedies can influence results. The company’s revenue growth, which was -17.3% year over year, and its profitMargin of 6.1% are points to observe when assessing business momentum. Because the stock is part of the CSI 300, movements in that index and in peer companies like Zhangzhou Pientzehuang Pharmaceutical (600436) or BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE (603392) can provide context for relative performance.